RNTs of A.M. Granov: Surfaktant-BL

Surfaktant-BL - the natural native medicine of surfactant selected from lungs of cattle close on structure and properties to surfactant of the easy person.

2020: The announcement of production of medicine for therapy of the main complication at a coronavirus

On March 27, 2020 it became known that in St. Petersburg medicine is produced for therapy of the main complication at a coronavirus.

As it was reported, the St. Petersburg biochemist and the pharmacologist, the doctor of medical sciences Oleg Rosenberg told that treatment of pneumonia, the most dangerous complication of a coronavirus, will allow to reduce death rate several times. The scientist reminded that in Russia the medicine which proved the efficiency in treatment of heavy pneumonia during epidemics of swine flu in 2009-2010 and 2015-2016 in Moscow, St. Petersburg, Tyumen, Pskov, Sochi, Nizhny Novgorod and other cities of Russia is developed. Death rate among the patients receiving pulmonary surfactant (TM Surfaktant-BL) together with antiviral medicine was very low, and at timely acceptance death rate was zero. For March, 2020 medicine is included in the VED list.

It is about developed in the Russian scientific center of radiology and surgical technologies of the academician A.M. Granov (the director of institute, the doctor of medical sciences — Dmitry Maystrenko) in St. Petersburg the medicine of pulmonary surfactant which passed clinical trials and permitted since 2008 for treatment of not cardiogenic pulmonary edema from which for March, 2020, generally and patients with a coronavirus die. Surfactant represents the difficult lipidic and proteinaceous complex which is on the surface of alveoluses. It provides a breath due to decrease in surface tension and interferes with adhesion of walls of alveoluses at an exhalation. Surfactant is synthesized by specialized cages - alveolotsita of the II type and selected for a surface of an alveolar epithelium.

The main complication which gives a coronavirus is pneumonia. Quite often, it develops quickly as the virus affects the lower airways (a throat, a trachea and bronchial tubes), and further inflammation passes to alveoluses. If it is not possible to suppress inflammatory process, pneumonia passes into not cardiogenic pulmonary edema (the medical name "sharp respiratory distress syndrome") of which more than a half of the patients who are on AVL (artificial ventilation of lungs) die. Patients enter into risk group of a heavy course of a disease 60 years and also people with different chronic diseases, such as diabetes, chronic heart failure, chronic obstructive pulmonary disease, etc. are more senior.

From the Russian Ministry of Health to RNTs of Granov the official request with a request was sent to report what medicines were developed what for March, 2020 are in development. In reply to departmental body the center directed the offer to use medicine of pulmonary surfactant for warning of development of viral pneumonia in patients with a coronavirus and prevention of death rate of elderly patients from its complications. The medicine created in Laboratory of medical biotechnology prevents development of complications in the form of heavy pneumonia at respiratory a distress a syndrome. For March, 2020 the answer from department did not arrive.

According to professor Oleg Rosenberg, this medicine of surfactant is the only medicine in world practice permitted for application for adults at severe damages of lungs. The Russian medicine differs from other medicines of surfactant in structure, it is received on original technology and has high medicinal properties.